Our senior associate Mr. Gordon Tsang acted as the Joint Company Secretary of Mabpharm Limited – B (stock code: 2181) (“Mabpharm”) in its successful listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) under Chapter 18A of the Hong Kong Main Board Listing Rules.
The shares of Mabpharm were listed on the Stock Exchange on 31 May 2019. The final offer price was HK$1.50 per share and the proceeds amounted to approximately HK$1.068 billion.
Mabpharm’s pipeline contains mAbs to treat cancer and autoimmune diseases, with three biosimilars in Phase III testing: CMAB007, a proposed biosimilar of dermatology and asthma drug Xolair omalizumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY); CMAB009, a proposed biosimilar of cancer drug Erbitux cetuximab from Eli Lilly and Co. (NYSE:LLY); and CMAB008, a proposed biosimilar for autoimmune drug Remicade infliximab from Johnson & Johnson (NYSE:JNJ).
Please contact Mr. Gordon Tsang for further information.